1-19 of 19
Lesley Seymour
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Available to Purchase
Eric Winquist, Sebastien J. Hotte, Kim Chi, Srikala Sridhar, Susan Ellard, Michael Ong, Nayyer Iqbal, Muhammad Salim, Urban Emmenegger, Joel R. Gingerich, Aly-Khan Lalani, Pierre Major, Christian Kollmannsberger, Steven Yip, Aaron Hansen, Daygen Finch, Christina Canil, James Hutchenreuther, Francisco Vera-Badillo, Martin Smoragiewicz, Michael Cabanero, Ming-Sound Tsao, Elie Ritch, Alexander W. Wyatt, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 45–55.
https://doi.org/10.1158/1078-0432.CCR-24-1612
Published: 06 January 2025
View articletitled, Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group

Available to Purchase
Alexander W. Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Chris A. Karlovich, Klaus Pantel, Joan Petrie, Reena Philip, Hillary S. Andrews, Paz J. Vellanki, Sofie H. Tolmeijer, Xenia Villalobos Alberu, Christian Alfano, Jan Bogaerts, Emiliano Calvo, Alice P. Chen, Rodrigo A. Toledo, Elisabeth G.E. de Vries, Lesley Seymour, Scott A. Laurie, Elena Garralda, for the RECIST ctDNA workshop group
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5034–5041.
https://doi.org/10.1158/1078-0432.CCR-24-1883
Published: 15 November 2024
View articletitled, Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Open the PDF for Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group in another window
Journal Articles

Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

Available to Purchase
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G.E. deVries
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 143–153.
https://doi.org/10.1158/1078-0432.CCR-21-3143
Published: 04 January 2023
View articletitled, Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response
Open the PDF for Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response in another window
Includes: Supplementary data
Journal Articles

Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

Available to Purchase
Martin Smoragiewicz, Alex A. Adjei, Emiliano Calvo, Josep Tabernero, Aurélien Marabelle, Christophe Massard, Jun Tang, Elisabeth G.E. de Vries, Jean-Yves Douillard, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2461–2465.
https://doi.org/10.1158/1078-0432.CCR-19-3136
Published: 01 June 2020
View articletitled, Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)
Open the PDF for Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT) in another window
Journal Articles

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

Available to Purchase
Anna V. Tinker, Holger W. Hirte, Diane Provencher, Marcus Butler, Heather Ritter, Dongsheng Tu, Hatem A. Azim, Jr, Paulo Paralejas, Nathalie Grenier, Shirley-Ann Hahn, Janelle Ramsahai, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6052–6060.
https://doi.org/10.1158/1078-0432.CCR-19-0298
Published: 15 October 2019
View articletitled, Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Open the PDF for Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221 in another window
Includes: Supplementary data
Journal Articles

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Available to Purchase
Geoffrey Liu, Sinead Cuffe, Shermi Liang, Abul Kalam Azad, Lu Cheng, Yonathan Brhane, Xin Qiu, David W. Cescon, Jeffrey Bruce, Zhuo Chen, Dangxiao Cheng, Devalben Patel, Brandon C. Tse, Scott A. Laurie, Glenwood Goss, Natasha B. Leighl, Rayjean Hung, Penelope A. Bradbury, Lesley Seymour, Frances A. Shepherd, Ming Sound Tsao, Bingshu E. Chen, Wei Xu, David N. Reisman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2460–2470.
https://doi.org/10.1158/1078-0432.CCR-16-1640
Published: 14 May 2017
View articletitled, BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Open the PDF for BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial in another window
Includes: Supplementary data
Journal Articles

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Available to Purchase
Lesley Seymour, Susan Groshen, Gary L. Rosner, Daniel M. Sullivan, David R. Spriggs, Steven Reeves, Amy Gravell, S. Percy Ivy, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5057–5063.
https://doi.org/10.1158/1078-0432.CCR-15-0035
Published: 12 November 2015
View articletitled, Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Open the PDF for Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee in another window
Journal Articles

Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials

Free
Philip A. Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, Steven R. Alberts, Paul J. Catalano, John Crowley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (16): 4176–4185.
https://doi.org/10.1158/1078-0432.CCR-13-2024
Published: 13 August 2014
View articletitled, Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials
Open the PDF for Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials in another window
Journal Articles

Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Available to Purchase
Channing J. Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia M. LoRusso, Laurence Baker, Larry Rubinstein, Erich Huang, Deborah Collyar, Susan Groshen, Steven Reeves, Lee M. Ellis, Daniel J. Sargent, Gary L. Rosner, Michael L. LeBlanc, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4210–4217.
https://doi.org/10.1158/1078-0432.CCR-14-0521
Published: 13 August 2014
View articletitled, Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Open the PDF for Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee in another window
Journal Articles

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

Available to Purchase
Patricia M. LoRusso, Scott A. Boerner, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1710–1718.
https://doi.org/10.1158/1078-0432.CCR-09-1993
Published: 14 March 2010
View articletitled, An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics
Open the PDF for An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics in another window
Journal Articles

Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan

Available to Purchase
Martin D. Forster, Nagahiro Saijo, Lesley Seymour, Hilary Calvert
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1737–1744.
https://doi.org/10.1158/1078-0432.CCR-09-2228
Published: 14 March 2010
View articletitled, Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan
Open the PDF for Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan in another window
Journal Articles

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

Available to Purchase
Lesley Seymour, S. Percy Ivy, Daniel Sargent, David Spriggs, Laurence Baker, Larry Rubinstein, Mark J. Ratain, Michael Le Blanc, David Stewart, John Crowley, Susan Groshen, Jeffrey S. Humphrey, Pamela West, Donald Berry
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1764–1769.
https://doi.org/10.1158/1078-0432.CCR-09-3287
Published: 14 March 2010
View articletitled, The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Open the PDF for The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee in another window
Journal Articles

Alternate Endpoints for Screening Phase II Studies

Available to Purchase
Neesha Dhani, Dongsheng Tu, Daniel J. Sargent, Lesley Seymour, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 1873–1882.
https://doi.org/10.1158/1078-0432.CCR-08-2034
Published: 16 March 2009
View articletitled, Alternate Endpoints for Screening Phase II Studies
Open the PDF for Alternate Endpoints for Screening Phase II Studies in another window
Journal Articles

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer

Available to Purchase
Eric Chen, Derek Jonker, Isabelle Gauthier, Martha MacLean, Julie Wells, Jean Powers, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1481–1486.
https://doi.org/10.1158/1078-0432.CCR-08-0761
Published: 19 February 2009
View articletitled, Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer
Open the PDF for Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer in another window
Journal Articles

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

Available to Purchase
Stephen Chia, Susan Dent, Susan Ellard, Peter M. Ellis, Ted Vandenberg, Karen Gelmon, Jean Powers, Wendy Walsh, Lesley Seymour, Elizabeth A. Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (2): 708–713.
https://doi.org/10.1158/1078-0432.CCR-08-1159
Published: 15 January 2009
View articletitled, Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
Open the PDF for Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer in another window
Journal Articles

Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10

Available to Purchase
Pascal Sève, Raymond Lai, Keyue Ding, Timothy Winton, Charles Butts, John Mackey, Charles Dumontet, Laith Dabbagh, Sarit Aviel-Ronen, Lesley Seymour, Marlo Whitehead, Ming-Sound Tsao, Frances A. Shepherd, Tony Reiman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 994–999.
https://doi.org/10.1158/1078-0432.CCR-06-1503
Published: 08 February 2007
View articletitled, Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10
Open the PDF for Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10 in another window
Journal Articles

Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval

Available to Purchase
John Goffin, Stefan Baral, Dongsheng Tu, Dora Nomikos, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5928–5934.
https://doi.org/10.1158/1078-0432.CCR-05-0130
Published: 22 August 2005
View articletitled, Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
Open the PDF for Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval in another window
Journal Articles

Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

Available to Purchase
Theodora Voskoglou-Nomikos, Joseph L. Pater, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4227–4239.
Published: 30 September 2003
View articletitled, Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models
Open the PDF for Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models in another window
Journal Articles

A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients

Available to Purchase
Manijeh Daneshmand, Doris A. E. Parolin, Holger W. Hirte, Pierre Major, Glenwood Goss, David Stewart, Gerald Batist, Wilson H. Miller, Jr., Sarah Matthews, Lesley Seymour, Ian A. J. Lorimer
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2457–2464.
Published: 01 July 2003
View articletitled, A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients
Open the PDF for A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients in another window